Previous 10 | Next 10 |
Target Hospitality ( TH ) +22% e xpanded partnership with Leading National Nonprofit Supporting Critical Humanitarian Aid Solutions. Annovis Bio ( ANVS ) +17% wins FDA nod to begin late-stage study for Parkinson's candidate. Grove Collaborative Holdings...
SAN FRANCISCO, July 05, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced ...
Agile Therapeutics ( AGRX ) -16% . Bed Bath & Beyond ( BBBY ) -13% on Q1 earnings release . Barnes & Noble Education ( BNED ) -15% on Q4 earnings release . Himax Technologies ( HIMX ) -12% . AeroVironment ( AVAV ) -...
89bio (ETNB) is down 4.8% after-hours after the firm has priced its previously announced underwritten public offering of 18.68M shares of its common stock and accompanying warrants to purchase up to 9.34M shares of common stock at a combined public offering price of $3.55 and, in li...
SAN FRANCISCO, June 29, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced ...
Gainers: Tactile Systems Technology (TCMD) +4.9%. Roth CH Acquisition (ROCC) +4.9%. Hertz Global Holdings (HTZ) +4.8%. WM Technology (MAPS) +4.7%. LendingTree (TREE) +4%. Losers: Icosavax (ICVX) -22.0%. AeroVironment (AVAV) -10.1%. Playa Hotels & Resorts (PLYA) -3.0%. 89bio (ETN...
89bio (NASDAQ:ETNB) shares dropped over 5% during Tuesday extended trading after the biopharmaceutical company proposed an underwritten public offering of $75M of shares of its common stock, pre-funded warrants and accompanying warrants to purchase shares of its common stock. Net pr...
A phase 2 trial of 89bio's (NASDAQ:ETNB) pegozafermin met its primary endpoint as a treatment of severe hypertriglyceridemia. Patients on pegozafermin saw clinically meaningful and significant reductions in triglycerides from baseline through week 8 across all doses. The highest dose saw the ...
SAN FRANCISCO, June 28, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced t...
- Trial met primary endpoint demonstrating statistically significant and clinically meaningful reductions across all doses (63% at the 27mg QW dose; p<0.001) in triglycerides (TG) from baseline; results were consistent in patients on or not on background therapy - - Observed ...
News, Short Squeeze, Breakout and More Instantly...
2024-06-21 09:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SAN FRANCISCO, May 22, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that data from the 48-week exten...
—With the initiation of ENLIGHTEN-Cirrhosis, pegozafermin is the first FGF21 analog to enter a Phase 3 trial in MASH patients with compensated cirrhosis (F4)— —Regression of fibrosis by histology at month 24 will serve as the basis for potential accelerated approval...